ABSTRACT
Objective: The purpose of this study was to evaluate changes in erythrocyte morphology associated with alectinib and resulting hemolytic anemia.
This was a retrospective analysis of patients with stage IV non-small-cell lung cancer (NSCLC) treated with alectinib. Erythrocyte morphology (by peripheral-blood film evaluation), hemogram, reticulocyte, direct Coombs tests, serum lactate dehydrogenase (LDH), haptoglobin, and indirect bilirubin levels were evaluated. Demographic characteristics of the patients were also collected.
In total, 13 patients (7 women) with a mean age of 52.0±10.5 years were included. Median pre-alectinib hemoglobin level was 12.1 g/dL [minimum (min): 9.4, maximum (max): 16.2 g/dL]. In total, serum hemoglobin was decreased in 8 patients (61.5%) compared with pre-alectinib levels. The average serum hemoglobin level after alectinib use was determined as 11.6 g/dL (min: 8.5 g/dL, max: 13 g/dL). Serum hemoglobin was <10 g/dL in only 3 patients. De novo anemia developed in six patients. Peripheral blood examination revealed numerous microsphero-acanthocytes, some echinocyte, rare fragmented erythrocytes, and generalized anisopoikilocytosis. Serum LDH levels were high in 6 of 13 patients (46.1%) receiving alectinib. Reticulocyte count was high in 10 of 13 patients (76.9%). A decrease in serum haptoglobin was observed in five patients (38.4%). Serum indirect bilirubin was high in two of the patients (15.3%).
Alectinib caused changes in the erythrocyte membrane and non-immune hemolysis in almost all patients using it. Hemolytic anemia was not severe enough to require alectinib dose reduction or discontinuation. Physicians caring for patients receiving alectinib should be alert to hematological changes due to drug use.
Keywords: Alectinib, non-immune hemolytic anemia, erythrocyte membrane changes
INTRODUCTION
Lung cancer is responsible for most cancer-related deaths worldwide (1). Among several types of cancer, non-small-cell lung cancer (NSCLC) constitutes more than 80% of all cases. The most commonly encountered subtypes of NSCLC are adenocarcinoma and squamous carcinoma. Compared with 1975, the 5-year survival rate in lung cancer increased by 9% to 20.5% in 2016 (2). Several factors account for this improvement in prognosis, the most important of which is the advent of targeted therapies and immunotherapy. Recent years have witnessed the discovery and elucidation of several genomic aberrations that are crucial in NSCLC pathogenesis. Almost 30% of patients with NSCLC have one or more of these mutations and rearrangements (3). A number of targeted therapies targeting these mutations enable improved survival, particularly in patients with advanced disease.
Anaplastic lymphoma kinase (ALK) rearrangements have been reported in up to 4.5% of patients with NSCLC (4). First discovered in 2007 (5), an inversion in chromosome 2p produces a fusion gene comprising the echinoderm microtubule-associated protein-like 4 (EML4) gene and the ALK gene. This fusion gene, in turn, activates the tyrosine kinase domain of the ALK gene, resulting in the proliferation of lung epithelial cells (6). The first targeted drug developed to address this important tumorigenic pathway was crizotinib, an ALK tyrosine kinase inhibitor (7). Owing to the observed beneficial effects, crizotinib was recommended as a first-line treatment agent in patients with ALK-rearranged NSCLC. However, with the advent of second- and third-generation ALK tyrosine kinase inhibitors with superior survival rates, better central nervous system penetration, and more acceptable adverse effect profiles, alectinib and ceritinib are now considered as first-line treatment in these patients (8, 9).
In a network meta-analysis, low-dose alectinib emerged as having the lowest adverse event risk among all ALK inhibitors (10). This does not mean that alectinib is not without adverse events (11). In the ALEX trial, adverse effects related to alectinib included constipation, liver function abnormalities, anemia (in 26% of the drug users), peripheral edema, myalgia, rash, and bradycardia. Most reported anemia cases were mild, and the median time to anemia development was 3.9 months (12). However, there were no data regarding the nature of alectinib-related anemia. After the publication of the ALEX trial (12), several case reports and series (13-15) reported a type of non-immune hemolytic anemia in patients with NSCLC treated with alectinib. These reports pointed to the development of erythrocyte membrane changes as the culprit triggering extravascular hemolysis in the spleen. Compared with the common use of alectinib, studies characterizing alectinib-related anemia are scarce. Thus, we aimed to report our experience with alectinib-induced non-immune hemolytic anemia.
METHODS
Patients and Setting
This is a retrospective analysis of patients with NSCLC who were treated with alectinib and developed nonimmune hemolytic anemia. The oncology departments of the University of Health Sciences Türkiye, Bakırköy Dr. Sadi Konuk Training and Research Hospital and Kartal Dr. Lütfi Kırdar City Hospital participated in the study. The University of Health Sciences Türkiye, Bakırköy Dr. Sadi Konuk Training and Research Hospital Clinical Research Ethics Committee approved the study protocol (decision no: 2022-17-01, date: 05.09.2022). We retrospectively screened NSCLC patients with ALK gene rearrangements and treated them with alectinib from the electronic hospital database and patient charts between January 2016 and April 2022. All NSCLC patients treated with alectinib were included in the study. Deceased patients at the time of screening and patients with missing data were excluded from the study.
Data Collection
Clinicodemographic characteristics such as age, sex, presence of comorbid conditions, ECOG performance status, disease stage during inclusion in the study, institution of curative-intent chemoradiotherapy, histologic subtype of NSCLC, percentage of ALK, and presence of organ metastases before alectinib treatment. We also performed laboratory tests (serum hemoglobin concentration, white blood cell count, platelet count) before alectinib treatment. Hemoglobin levels were measured after alectinib treatment. In addition, we performed hemolysis tests and other tests to better elucidate alectinib-related anemia. These tests involved serum hemoglobin concentration, serum vitamin B12, folic acid, and ferritin levels, serum lactate dehydrogenase (LDH), total and direct bilirubin, haptoglobin levels, direct and indirect Coombs tests, reticulocyte count, peripheral smear, and paroxysmal nocturnal hemoglobinuria panel. Response to alectinib therapy was classified as complete or partial response, stable disease, and progression. We also collected data regarding adverse events (AE) related to alectinib use. Common Terminology Criteria for Adverse Events v3.0 was used to grade observed AE as follows: Grade 1, Mild AE; grade 2, Moderate AE; grade 3, Severe AE; grade 4, life-threatening or disabling AE; and grade 5, death related to AE (16).
Statistical Analysis
Categorical variables are reported as numbers and percentages (%). Continuous variables are given as mean ± standard deviation or median [minimum (min) - maximum (max)] depending on the distribution of the variable. The Wilcoxon signed-rank test was used to evaluate the statistical significance of pre- and post- alectinib serum LDH values, and the paired samples t-test was used for comparing serum hemoglobin values. Statistical analyses were performed by processing the data of the patients with the SPSS v22 (IBM, New York) program.
RESULTS
General Characteristics
We obtained data of 13 patients via screening of the hospital database and records of oncology departments. None of the patients were excluded from the study. Overall, 13 patients (7 females) with a mean age of 52.0±10.5 years were included in the study. All patients had stage 4 NSCLC with an adenocarcinoma subtype. All patients had one or more distant organ metastases. The most common organ metastasis was to the bone (9/13), followed by the brain (5/13). Six of 13 patients were administered cytotoxic chemotherapy before the institution of alectinib. In all cases, the chemotherapy regimen involved a carboplatin + taxane combination. Three patients showed a complete response to alectinib therapy, eight patients had a partial response, and one patient had stable disease under alectinib therapy. The mean duration of alectinib use was 26.3±15.7 months. Eight of 13 patients (57.1%) developed at least one AE other than anemia related to alectinib use. All observed AEs were grade 1 or 2. No dose reduction or drug discontinuation was not needed because of AEs. Only one patient (patint number 14) required red blood cell (RBC) transfusion because of anemia during her disease. All patients were alive during data collection for this study. Table 1 shows the demographic and clinical characteristics of the study patients.
Anemia Parameters
Before alectinib treatment, 9 of 13 patients already had anemia. The median pre-alectinib hemoglobin level was 12.1 g/dL (min: 9.4, max: 16.2 g/dL). In total, 8 patients (61.5%) had reduced serum hemoglobin levels compared with pre-alectinib hemoglobin levels. The mean serum hemoglobin level after alectinib use was 11.6 g/dL (min: 8.5 g/dL, max: 13 g/dL). Only three patients had serum hemoglobin values below 10 g/dL. De novo anemia developed in 6 of 13 patients (patients nos 2, 4, 6, 8, 10, and 13). There was no statistically significant change in the mean hemoglobin values of patients before and after alectinib use (p=0.091, the paired samples t-test). Table 2 depicts the laboratory values of the patients.
In all patients, except patient 8, peripheral blood film demonstrated numerous microsphero-acanthocytes, some echinocytes, rare fragmented erythrocytes, and general anisopoikilocytosis (Figure 1). Patient number 8 showed no erythrocyte membrane changes but had an iron deficiency anemia morphology. However, her serum ferritin level was within the normal range. In patient 10, the peripheral smear showed normochromic normocytic erythrocytes with rare acanthocytes.
Other Laboratory Studies
Serum LDH levels were elevated before alectinib treatment in 3 of 11 patients (27.2%). With alectinib treatment, 6 of 13 patients (46.1%) had elevated LDH levels. Median serum LDH levels before and during alectinib use were 210 U/L and 203 U/L, respectively (p=0.110, the Wilcoxon signed-rank test). Ten of 13 patients (76.9%) had elevated reticulocyte counts. Direct and indirect Coombs tests were negative in all patients. At the time of evaluation, serum haptoglobin levels were reduced in only 5 patients (38.4%). Serum indirect bilirubin levels were elevated in only 2 of the patients (15.3%).
DISCUSSION
The most salient findings of the present study were as follows: (i) Alectinib led to non-immune hemolytic anemia in all patients who used it. (ii) None of the patients required alectinib dose reduction or cessation due to anemia. (iii) RBC morphological alterations were observed in all patients. (iv) Hemolytic anemia was nonimmune in all alectinib users. (v) The most prominent morphologic change in RBCs was the development of acanthocytosis.
We evaluated the presence and characteristics of anemia in patients with stage IV NSCLC. Our results showed the occurrence of anemia in all alectinib users. In contrast to the universal development of hemolytic anemia in our cohort related to alectinib use, clinical trials reported the development of anemia between 14-22% of patients in whom alectinib was used (12, 17). Unfortunately, these trials did not provide details of the anemia type. One case series by Gullapalli et al. (18) reported alectinib-related hemolytic anemia in six patients, but they did not reveal among how many alectinib users they selected these six patients. Kunz et al. (15) conducted a prospective observational study in which they reported the development of reticulocytosis and abnormal erythrocyte morphology with anisocytosis in all 24 patients who were treated with alectinib within 2 weeks of its use. Our results are in agreement with those of the latter authors in that alectinib caused RBC morphologic changes and nonimmune hemolytic anemia in all treated patients.
We report the third largest case series after Kuzich et al. (13) and Kunz et al. (15), in which alectinib-related hemolytic anemia was characterized. To the best of our knowledge, 64 cases have been reported in the literature to date.
Alectinib-induced RBC membrane changes were first described by Kuzich et al. (13). The authors retrospectively evaluated 43 patients with advanced NSCLC and observed marked acanthocytosis, echinocytosis, and/or spheroacanthocytosis in 95% of the alectinib-treated patients. However, anemia developed only in 73% of the patients and was mild to severity. Serum hemoglobin values were <10 g/dL in 38% and <8 g/dL in only 8% of the patients. Kunz et al. (15) found RBC membrane changes in all treated patients. The most commonly encountered morphological abnormality was acathopcytes, followed by echinocyte, spherocytes, dacrocytes, and fragmentocytes. Anemia was present in only 68% of the patients treated with alectinib in Kunz et al. (15). The peripheral blood film of our patients showed widespread acanthocytosis, except in one patient. Among our patients, anemia was present in 61.5% of the patients with alectinib use. However, the de novo anemia rate related to alectinib use was 46%. There was no severe anemia, and only two patients had serum hemoglobin levels below 10 g/dL. None of our patients required alectinib dose reduction or discontinuation because of the development of anemia.
The exact mechanism of alectinib-induced alterations in the RBC membrane is yet to be elucidated. However, Kuzich et al. (13) and others (15) showed reduced eosin-5-maleimide staining (EMA) binding in affected patients. This finding, along with apparent morphologic changes, implies that alectinib leads to erythrocyte cytoskeletal changes. Apart from one case by Okumoto et al. (19), all reported alectinib-induced anemia cases in the literature were nonimmune and extravascular. The direct antiglobulin (Coombs) test was consistently found to be negative in reported cases. Okumoto et al. (19) reported alectinib-induced hemolytic anemia, and the Coombs test was negative. Nevertheless, the authors concluded that their case was Coombs-negative immune hemolytic anemia. We believe that the authors actually detected non-immune hemolytic anemia precipitated by alectinib-induced RBC membrane changes but erroneously labeled this as Coombs-negative immune hemolytic anemia. In our cohort, similar to the literature, all patients had negative direct and indirect Coombs tests.
In our study, reticulocyte counts were increased in 76.9% of the patients. The highest reticulocyte count was 4.23%. The results of Kuzich et al. (13) were similar to ours in terms of reticulocyte counts. It was available for seven of their patients (elevated in four), and the maximum value was 3.6%. On the other hand, in the study by Kunz et al. (15), 87.5% of the patients had elevated reticulocyte counts, and the maximum value was 8.3%. In our opinion, the discrepancy between the reticulocyte counts between our results and those by Kunz et al. (15) results from the study design difference. Kunz et al. (15) conducted a prospective study and had the opportunity to prospectively evaluate the patients at monthly intervals after alectinib initiation. Thus, they might have caught the most manifest time of alectinib-induced hemolysis. In contrast, in our evaluation, some patients had been on alectinib treatment for several months. Interestingly, reticulocyte elevation was still evident in three-fourths of our patients, and the counts were somehow smaller compared with those of patients by Kunz et al. (15).
Some limitations of this study deserve mention: First, ours was a retrospective study. Thus, we may have missed some relevant data due to the progress of RBC changes and resultant hemolysis. Second, we did not perform an EMA binding test or other investigations related to ultrastructural changes in the erythrocyte membrane. Thus, we cannot draw any conclusions as to the exact mechanism of the RBC membrane changes that were evident in the light microscopic evaluation. However, studies of some groups mentioned earlier shed some light on the underpinnings of acathocyte development with alectinib use. EMA binging was uniformly diminished, pointing to a possible effect of alectinib on the RBC membrane structure. However, we still do not know by what mechanism alectinib can alter the membrane structure. Third, we cannot determine whether this observed effect of alectinib is specific to alectinib or a class effect. Other studies in the literature have not observed changes in RBCs similar to alectinib with the use of other ALK inhibitors such as crizotinib, brigatinib, and lorlatinib (15). Lastly, we cannot determine whether alectinib-related changes in RBC membranes are temporary because all of our patients were still using their alectinib treatments at the time of the evaluation. However, other researchers have reported that RBC membrane changes were corrected upon discontinuation of alectinib use (15).
CONCLUSION
In conclusion, in this third-largest study regarding the effects of alectinib on RBCs, we showed that alectinib caused erythrocyte membrane changes and nonimmune hemolyses in almost all patients who used it. Hemolytic anemia was not severe, necessitating drug dose reduction or discontinuation. However, it is of utmost importance to know alectinib-related hematologic changes beforehand so that lengthy and expensive studies can be undertaken to investigate the cause of anemia and hemolysis in alectinib-treated patients.
ETHICS
Ethics Committee Approval: The University of Health Sciences Türkiye, Bakırköy Dr. Sadi Konuk Training and Research Hospital Clinical Research Ethics Committee approved the study protocol (decision no: 2022-17-01, date: 05.09.2022).
Informed Consent: Retrospective study.
